Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Subscribe To Our Newsletter & Stay Updated
